youtube_live
Q3 2026 earnings • released • EPS beat +17.95%
See resultschevron_right
DFTX:NASDAQ
Definium Therapeutics Inc
$32.08
arrow_downward
-2.79%(-0.92) 1D
$32.16
arrow_upward
+0.25% (+0.080)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DFTX...
Open
$32.70
High
$32.70
Low
$31.47
Mkt. cap
4.39B
Avg. vol.
1.83M
Volume
778.19K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.02
Beta
2.23
Shares outstanding
136.90M
No. of employees
106
Open
$32.70
High
$32.70
Low
$31.47
Mkt. cap
4.39B
Avg. vol.
1.83M
Volume
778.19K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.02
Beta
2.23
Shares outstanding
136.90M
No. of employees
106
News stories
From web sources and news partners
Yahoo Finance
·
2 days ago
How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
Yahoo Finance Singapore
·
2 days ago
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitedefiniumtx.com